Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | ACACB | O00763 | 4/20 | 0.44 |
| ▸ | ACACA | Q13085 | 4/20 | 0.44 |
| ▸ | NPC1L1 | Q9UHC9 | 2/20 | 0.43 |
| ▸ | EEF2K | O00418 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | CCRL2 | O00421 | 1/20 | 0.40 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6331356 | 0.85 | MAP4K4 (0.49) | NPC1L1 | |
| SCHEMBL6326733 | 0.82 | HCRTR1 (0.41) | KMT2AACACBACACANPC1RAB9A | |
| SCHEMBL6330326 | 0.81 | ADORA2A (0.45) | — | |
| SCHEMBL4150819 | 0.74 | HPGD (0.56) | ALDH1A1 | |
| SCHEMBL6323082 | 0.74 | HPGD (0.52) | KMT2AALDH1A1 | |
| SCHEMBL6324733 | 0.73 | HPGD (0.58) | ALDH1A1 | |
| SCHEMBL4141349 | 0.72 | ACACB (0.40) | ACACBACACACCRL2ALDH1A1 | |
| SCHEMBL4144760 | 0.72 | ACACB (0.40) | ACACBACACACCRL2ALDH1A1 | |
| SCHEMBL26230079 | 0.72 | IRAK1 (0.51) | ACACBACACAIRAK1CCRL2 | |
| SCHEMBL3285436 | 0.71 | PKM (0.61) | ACACBACACANPC1L1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050107409-A1 | Aromatic bicyclic compounds, preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-05-19 | — | — | US | disclosed |
| WO-2004080970-A1 | NOVEL BICYCLIC AROMATIC COMPOUNDS, THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107409-A1 | Aromatic bicyclic compounds, preparation thereof and their use as pharmaceutical compositions | F12, F2, F11 | KMT2A 3506/4885ACACB 2102/4885ACACA 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.